

Appl No. 10/020,541  
Reply to Office action of January 13, 2005

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-15. (Cancelled)

16. (Currently amended) A method of protecting ocular neural tissue from damage caused by photodynamic therapy (PDT) treatment comprising delivering a composition to a patient's ocular neural tissue, the composition comprising an amount of a ~~neuroprotectant compound~~ brimonidine effective to protect a plurality of ocular neurons from cell death caused by a photoactive component of the PDT treatment as compared to ocular neuron cell death observed in the absence of the administration of said neuroprotectant.

17. (Cancelled)

18. (Currently amended) The method of claim 16 wherein said ~~neuroprotectant compound~~ brimonidine is administered at a time sufficiently before said PDT treatment to permit localization within ocular tissue prior to said treatment.

19. (Currently amended) The method of claim 16 wherein said ~~neuroprotectant compound~~ brimonidine is administered intravenously.

Appl. No. 10/020,541

Reply to Office action of January 13, 2005

20. (Currently amended) The method of claim 16 wherein said ~~neuroprotectant compound~~ brimonidine is administered through intraocular injection.

21. (Currently amended) The method of claim 16 wherein said ~~neuroprotectant compound~~ brimonidine is administered by subretinal injection.

22. (Currently amended) The method of claim 16 wherein said ~~neuroprotectant compound~~ brimonidine is administered by intravitreal injection.

23-29. (Cancelled)

30. (Currently amended) The method of any of the preceding claims 16-22 wherein said composition also comprises ~~an therapeutically effective amount of a antiangiogenic compound~~ a therapeutically effective amount of an antiangiogenic compound.

31-38. (Cancelled)